02:33 , Jul 13, 2019 |  BioCentury  |  Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

The performance of 1H19 IPOs point toward a continuation of a dual-class system where biotechs backed by deep-pocketed VCs and crossover investors can tap the public market at will and generate stronger after-market performance than...
17:10 , Jan 25, 2019 |  BC Week In Review  |  Financial News

Bellerophon prices $7M follow-on

Cardiopulmonary disease company Bellerophon Therapeutics Inc. (NASDAQ:BLPH) raised $7 million through the sale of 10 million shares at $0.70 in a follow-on on Jan. 23. The price is a 20% discount to Bellerophon's close of...
18:42 , Aug 10, 2018 |  BC Week In Review  |  Clinical News

Phase III of Bellerophon's INOpulse for PAH stopped for futility

Bellerophon Therapeutics Inc. (NASDAQ:BLPH) said a DMC recommended stopping for futility the Phase III INOvation-1 trial of INOpulse to treat pulmonary arterial hypertension (PAH). A prespecified interim analysis of the first 75 patients who completed...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
19:50 , Oct 13, 2017 |  BC Week In Review  |  Financial News

Bellerophon raises $23.4 million in private placement

On Sept. 27, cardiopulmonary disease company Bellerophon Therapeutics Inc. (NASDAQ:BLPH) raised $23.4 million in a private placement through the sale of about 19.4 million shares. The financing was led by Puissance Capital Management and Venrock...
20:48 , Jan 13, 2017 |  BC Week In Review  |  Clinical News

INOpulse regulatory update

Bellerophon said FDA could approve INOpulse for pulmonary arterial hypertension (PAH) as early as 2020 after the agency accepted changes to INOpulse’s Phase III program. Bellerophon will now replace the planned Phase III INOvation-2 trial...
00:11 , Dec 1, 2016 |  BC Week In Review  |  Financial News

Bellerophon completes private placement

Bellerophon raised $12 million through the sale of 17.1 million units at $0.70 in a private placement. Each unit comprises a share and a five-year warrant to purchase a share at $0.80. H.C. Wainwright is...
07:00 , Oct 31, 2016 |  BC Week In Review  |  Financial News

Bellerophon Therapeutics proposes private placement of common stock and warrants

Bellerophon Therapeutics Inc. (NASDAQ:BLPH), Hampton, N.J.  Business: Cardiovascular, Pulmonary  Date announced: 2016-10-25  Type: Private placement of common stock and warrants  To be raised: Up to $24 million  Shares: TBD  Price Prior: $1.48  Shares outstanding prior:...
07:00 , Jul 11, 2016 |  BC Week In Review  |  Clinical News

INOpulse: Phase III started

Bellerophon began the double-blind, placebo-controlled, international Phase III INOvation-1 trial to evaluate 15 and 75 ug/kg per hour inhaled NO with INOpulse as add-on therapy in about 188 patients. The company has an SPA from...
07:00 , Oct 19, 2015 |  BC Week In Review  |  Clinical News

INOpulse: Interim Phase II data

Interim data from 20 PAH patients on long-term oxygen therapy in Part 2 of a double-blind, placebo-controlled, crossover, North American Phase II trial showed that 75 ug/kg per hour INOpulse for 8-12 months led to...